By providing your email address and/or phone number, you are agreeing to receive transactional, product, supply information communications from Pfizer Inc. Message and data rates may apply for SMS messages sent to your mobile phone.

ATGAM Sterile Solution contains lymphocyte immune globulin, anti-thymocyte globulin [equine]. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric IgG, from hyperimmune serum of horses immunized with human thymus lymphocytes. ATGAM is a transparent to slightly opalescent aqueous protein solution.

ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine] sterile solution) This product information is intended only for residents of the United States. for Consumers: ATGAM - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources; for Healthcare professionals:

ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine]) is a treatment for aplastic anemia and renal allograft rejection. Information for HCPs. Atgam

ATGAM sterile solution contains lymphocyte immune globulin, anti-thymocyte globulin (equine). It is the purified, concentrated, and sterile gamma globulin, primarily monomeric IgG, from hyperimmune serum of horses immunized with human thymus lymphocytes. ATGAM is a transparent to slightly opalescent aqueous protein solution.

Tradename: ATGAM Manufacturer: Pharmacia & Upjohn Company LLC, a Pfizer company Indications: Renal transplant rejection.

Monitor patients for signs and symptoms of anaphylaxis during infusion and for at least 24 hours after infusion [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. ATGAM is an immunoglobulin G indicated for: For intravenous use only. ATGAM 50 mg/mL concentrate for solution for infusion. (3)

ATGAM is indicated for the treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation [see Clinical Studies (14.2)]. The usefulness of ATGAM has not been demonstrated in patients with aplastic anemia who are suitable

ATGAM is a united kingdom trademark and brand of Pharmacia Limited, CT13 9NJ, UNITED KINGDOM. This trademark was filed to UKIPO on Tuesday, June 21, 1977. The ATGAM is under the trademark classification: Pharmaceutical Products; The ATGAM trademark covers Immunosuppressant agents.

Antithymocyte immunoglobulin is used for the prevention and treatment of graft rejection after solid organ transplantation, usually in combination with other immunosuppressive drugs. Below package inserts are available for further reading: